Virtual Tumor Board: Optimizing Personalized Care Plans for Patients With Relapsed/Refractory Follicular Lymphoma

STATEMENT OF NEED

Of the estimated 74,200 new cases of non-Hodgkin lymphoma each year in the United States, approximately 22% are FL, an indolent, difficult-to-treat B-cell malignancy (ACS, 2019; NCCN, 2019). Most patients are diagnosed at an average age of 63 years (NCI, 2019). Despite the introduction of novel therapies during the past decade, complications such as delayed presentation and treatment and evolving disease subtypes continue to hamper patient outcomes, and multiple recurrences with available therapies are common (NCCN, 2019). Currently, allogeneic hematopoietic stem cell transplant is the only curative therapeutic modality for relapsed/refractory disease. However, the risk for comorbidities and secondary cancers limits the utility of this treatment upfront. Further research is required to determine the optimal timing and role of transplant and novel therapies to keep the remission rate among FL patients high and durable (NCCN, 2019).

TARGET AUDIENCE

Community oncologists, hematologists, pathologists, oncology advanced practitioners, and other health care professionals involved in the treatment of patients with follicular lymphoma.

LEARNING OBJECTIVES

Upon completion of this activity, participants should be able to:

1.) Evaluate emerging efficacy and safety data on novel therapeutic approaches for patients with relapsed/refractory FL
2.) Discuss the implications of POD24 status in therapeutic decision making for patients with relapsed/refractory FL
3.) Apply strategies to optimize treatment experiences and outcomes for patients with relapsed/refractory FL